前列腺癌（PC）是全球男性诊断次数第二多的癌症。尽管在发病率和死亡率方面存在种族和民族差异，但越来越多的数据表明，新诊断PC的男性中，种族间的结局相似。然而，除了黑人/白人之外的种族在结局方面的研究很少。此外，在所有已转移的前列腺癌（mPC）患者中，结局是否因种族而异仍不清楚。本系统文献综述（SLR）对当前关于种族与mPC患者生存率相关的证据进行了全面综合。按照PRISMA指南，进行了一次SLR，并进行了报告。使用Ovid®接口搜索了从2012年1月至2022年7月发表的现实世界研究的MEDLINE®，Embase和Cochrane Library。还进行了对关键会议的补充搜索。评估了风险偏倚。识别出3228条独特记录中，包括62条记录（47篇全文和15篇会议摘要），对应于54个关于种族与生存率的独立研究（51个美国和3个非美国国家）。大多数研究显示黑人与白人患者在总生存期（OS）（n = 21/27）或前列腺癌特异性死亡率（PCSM）（n = 8/9）方面没有差异，但大多数研究显示，黑人患者在某些mPC治疗中表现出改善的OS（n = 7/10）。大多数研究发现白人患者与西班牙裔（OS：n = 6/8; PCSM：n = 5/6）或美洲印第安人/阿拉斯加原住民（AI/AN）（OS：n = 2/3; PCSM：n = 5/5）之间没有生存差异。大多数研究发现亚洲患者的OS（n = 3/4）和PCSM（n = 6/6）相对于白人患者有所改善。大多数研究发现黑人、西班牙裔和AI/AN患者与白人患者的mPC患者具有相似的存活率，而在某些治疗中黑人患者和亚洲患者的生存率有所提高。未来的研究需要进一步了解包括健康社会决定因素在内的种族的哪些方面驱动了这些发现。© 2023. 作者们。

Prostate cancer (PC) is the second most diagnosed cancer in men worldwide. While racial and ethnic differences exist in incidence and mortality, increasing data suggest outcomes by race among men with newly diagnosed PC are similar. However, outcomes among races beyond Black/White have been poorly studied. Moreover, whether outcomes differ by race among men who all have metastatic PC (mPC) is unclear. This systematic literature review (SLR) provides a comprehensive synthesis of current evidence relating race to survival in mPC.An SLR was conducted and reported in accordance with PRISMA guidelines. MEDLINE®, Embase, and Cochrane Library using the Ovid® interface were searched for real-world studies published from January 2012 to July 2022 investigating the impact of race on overall survival (OS) and prostate cancer-specific mortality (PCSM) in patients with mPC. A supplemental search of key congresses was also conducted. Studies were appraised for risk of bias.Of 3228 unique records identified, 62 records (47 full-text and 15 conference abstracts), corresponding to 54 unique studies (51 United States and 3 ex-United States) reporting on race and survival were included. While most studies showed no difference between Black vs White patients for OS (n = 21/27) or PCSM (n = 8/9), most showed that Black patients demonstrated improved OS on certain mPC treatments (n = 7/10). Most studies found no survival difference between White patients and Hispanic (OS: n = 6/8; PCSM: n = 5/6) or American Indian/Alaskan Native (AI/AN) (OS: n = 2/3; PCSM: n = 5/5). Most studies found Asian patients had improved OS (n = 3/4) and PCSM (n = 6/6) vs White patients.Most studies found Black, Hispanic, and AI/AN patients with mPC had similar survival as White patients, while Black patients on certain therapies and Asian patients showed improved survival. Future studies are needed to understand what aspects of race including social determinants of health are driving these findings.© 2023. The Author(s).